
{
  "documentMetadata": {
    "title": "Tuberculosis, Latent",
    "sourceFile": "syndromes/infectious_syndromes/Tuberculosis, Latent.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Latent Tuberculosis Infection (LTBI)"
    },
    {
      "type": "paragraph",
      "text": "Latent tuberculosis infection (LTBI) is a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifest active TB. Individuals with LTBI are asymptomatic and not infectious."
    },
    {
      "type": "header",
      "level": 2,
      "text": "Diagnosis"
    },
    {
      "type": "diagnosticTest",
      "diagnosticTestData": {
        "name": "Tuberculin Skin Test (TST)",
        "interpretation": "Induration size is interpreted based on risk factors. A positive test indicates TB infection but does not distinguish between latent and active disease."
      }
    },
    {
      "type": "diagnosticTest",
      "diagnosticTestData": {
        "name": "Interferon-Gamma Release Assays (IGRAs)",
        "sampleType": "Blood",
        "interpretation": "Measures T-cell release of interferon-gamma in response to M. tuberculosis antigens. Like TST, a positive test does not distinguish between latent and active TB."
      }
    },
    {
      "type": "procedure",
      "procedureData": {
          "name": "Chest X-ray",
          "indication": "To rule out active pulmonary TB in all persons diagnosed with LTBI.",
          "timing": "Required before starting treatment for LTBI."
      }
    },
    {
      "type": "header",
      "level": 2,
      "text": "Treatment Regimens for Latent TB Infection"
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "prophylaxis",
        "strengthOfRecommendation": "Recommended",
        "appliesTo": {
            "description": "Most persons with LTBI"
        },
        "components": [
          { "drug": "Isoniazid", "route": "PO", "frequency": "Daily" },
          { "drug": "Rifampin", "route": "PO", "frequency": "Daily", "connector": "+" }
        ],
        "durationDetail": {
          "fixedDuration": "3 months"
        },
        "notes": "Also referred to as 3HR. A preferred short-course regimen."
      }
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "prophylaxis",
        "strengthOfRecommendation": "Recommended",
        "components": [
          { "drug": "Isoniazid", "route": "PO", "frequency": "Daily" },
          { "drug": "Rifapentine", "route": "PO", "frequency": "Weekly", "connector": "+" }
        ],
        "durationDetail": {
          "fixedDuration": "3 months"
        },
        "notes": "Also referred to as 3HP. Administered as once-weekly therapy for 12 weeks. Not recommended for pregnant women or children <2 years old."
      }
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "prophylaxis",
        "strengthOfRecommendation": "Recommended",
        "components": [
          { "drug": "Rifampin", "route": "PO", "frequency": "Daily" }
        ],
        "durationDetail": {
          "fixedDuration": "4 months"
        },
        "notes": "Also referred to as 4R. A preferred short-course regimen, especially for those with contraindications to isoniazid."
      }
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "prophylaxis",
        "strengthOfRecommendation": "Alternative",
        "components": [
          { "drug": "Isoniazid", "route": "PO", "frequency": "Daily" }
        ],
        "durationDetail": {
          "fixedDuration": "6 or 9 months"
        },
        "notes": "6H or 9H. Longer duration regimens, now less favored than shorter-course options due to lower completion rates and higher toxicity risk."
      }
    }
  ]
}
